Drug-Resistant Epilepsy Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | ES Therapeutics, PhytoTech Therapeutics, UCB Biopharma, SK Life Scieences

Posted on
by

Drug-Resistant Epilepsy Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | ES Therapeutics, PhytoTech Therapeutics, UCB Biopharma, SK Life Scieences
DelveInsight’s “Drug-Resistant Epilepsy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Drug-Resistant Epilepsy, historical and forecasted epidemiology as well as the Drug-Resistant Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Drug-Resistant Epilepsy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Drug-Resistant Epilepsy, historical and forecasted epidemiology as well as the Drug-Resistant Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Drug-Resistant Epilepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Drug-Resistant Epilepsy Market Forecast

 

Some of the key facts of the Drug-Resistant Epilepsy Market Report: 

  • The Drug-Resistant Epilepsy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Refractory epilepsy will eventually develop in about one-third of patients with epilepsy. This indicates that medications are either ineffective at controlling seizures altogether
  • According to a study by Sirven et al. (2020) titled “Evaluation and management of drug-resistant epilepsy,” up to about 20–40% of epilepsy patients (or over 400,000 persons living in the US) may have refractory epilepsy
  • In a study named “Epidemiology of drug-resistant epilepsy” that was conducted in Germany, N’guyen et al. (2018) found that the prevalence of epilepsy in industrialized countries was approximately 5 per 1000 people. According to research, 30–40% of epileptic individuals had some degree of seizure activity. Additionally, up to 70% of patients developed non-idiopathic partial epilepsy
  • Key Drug-Resistant Epilepsy Companies: PTC Therapeutics, MGC Pharmaceuticals, iQure Pharma, ES Therapeutics, SK Life Science, UCB Biopharma, and others
  • Key Drug-Resistant Epilepsy Therapies: Vatiquinone, MGCND00EP1, iQ-007, ES-481, PLT101, UCB0942, RWJ-333369, Padsevonil, ataluren, RWJ 333369, and others
  • The Drug-Resistant Epilepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Drug-Resistant Epilepsy pipeline products will significantly revolutionize the Drug-Resistant Epilepsy market dynamics.

 

Drug-Resistant Epilepsy Overview

Drug-resistant epilepsy, also known as intractable epilepsy or refractory epilepsy, is defined as the inability to achieve prolonged seizure independence after an adequate number of trials with two antiepileptic medication regimens that were properly selected, tolerated, and utilized (either as monotherapy or in combination).

 

Get a Free sample for the Drug-Resistant Epilepsy Market Report 

https://www.delveinsight.com/report-store/drug-resistant-epilepsy-market

 

Drug-Resistant Epilepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Drug-Resistant Epilepsy Epidemiology Segmentation:

The Drug-Resistant Epilepsy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Drug-Resistant Epilepsy
  • Prevalent Cases of Drug-Resistant Epilepsy by severity
  • Gender-specific Prevalence of Drug-Resistant Epilepsy
  • Diagnosed Cases of Episodic and Chronic Drug-Resistant Epilepsy

 

Download the report to understand which factors are driving Drug-Resistant Epilepsy epidemiology trends @ Drug-Resistant Epilepsy Epidemiology Forecast

 

Drug-Resistant Epilepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Drug-Resistant Epilepsy market or expected to get launched during the study period. The analysis covers Drug-Resistant Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Drug-Resistant Epilepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Drug-Resistant Epilepsy Therapies and Key Companies

  • Vatiquinone: PTC Therapeutics
  • MGCND00EP1: MGC Pharmaceuticals
  • iQ-007: iQure Pharma
  • ES-481: ES Therapeutics
  • PLT101: PhytoTech Therapeutics, Ltd.
  • UCB0942: UCB Biopharma
  • RWJ-333369: SK Life Science,
  • Padsevonil: UCB Biopharma
  • ataluren: PTC Therapeutics
  • RWJ 333369: SK Life Science, Inc.

 

Discover more about therapies set to grab major Drug-Resistant Epilepsy market share @ Drug-Resistant Epilepsy Treatment Market

 

Drug-Resistant Epilepsy Market Strengths

  • Growing Focus On Providing Seizure-Free Life To Fuel Innovations.
  • Growth in The Demand For Epileptic Seizures Treatment

 

Drug-Resistant Epilepsy Market Opportunities

  • Growing funding for R&D of epilepsy is also contributing as a factor for the market growth.
  • Rising neurological diseases among population will also propel the growth of the market Increasing brain injuries cases due to road accidents will also drive the growth of this market

 

Scope of the Drug-Resistant Epilepsy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Drug-Resistant Epilepsy Companies: PTC Therapeutics, MGC Pharmaceuticals, iQure Pharma, ES Therapeutics, SK Life Science, UCB Biopharma, and others
  • Key Drug-Resistant Epilepsy Therapies: Vatiquinone, MGCND00EP1, iQ-007, ES-481, PLT101, UCB0942, RWJ-333369, Padsevonil, ataluren, RWJ 333369, and others
  • Drug-Resistant Epilepsy Therapeutic Assessment: Drug-Resistant Epilepsy current marketed and Drug-Resistant Epilepsy emerging therapies
  • Drug-Resistant Epilepsy Market Dynamics: Drug-Resistant Epilepsy market drivers and Drug-Resistant Epilepsy market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Drug-Resistant Epilepsy Unmet Needs, KOL’s views, Analyst’s views, Drug-Resistant Epilepsy Market Access and Reimbursement 

 

To know more about Drug-Resistant Epilepsy companies working in the treatment market, visit @ Drug-Resistant Epilepsy Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Drug-Resistant Epilepsy Market Report Introduction

2. Executive Summary for Drug-Resistant Epilepsy

3. SWOT analysis of Drug-Resistant Epilepsy

4. Drug-Resistant Epilepsy Patient Share (%) Overview at a Glance

5. Drug-Resistant Epilepsy Market Overview at a Glance

6. Drug-Resistant Epilepsy Disease Background and Overview

7. Drug-Resistant Epilepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Drug-Resistant Epilepsy 

9. Drug-Resistant Epilepsy Current Treatment and Medical Practices

10. Drug-Resistant Epilepsy Unmet Needs

11. Drug-Resistant Epilepsy Emerging Therapies

12. Drug-Resistant Epilepsy Market Outlook

13. Country-Wise Drug-Resistant Epilepsy Market Analysis (2019–2032)

14. Drug-Resistant Epilepsy Market Access and Reimbursement of Therapies

15. Drug-Resistant Epilepsy Market Drivers

16. Drug-Resistant Epilepsy Market Barriers

17.  Drug-Resistant Epilepsy Appendix

18. Drug-Resistant Epilepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services